Studies have shown that about 90% of patients with premature ovarian failure are infertile at the time of initial diagnosis; about 50% of patients will have a transient recovery of ovarian function but a natural pregnancy rate of less than 5%. Therefore, for patients with premature ovarian failure who have fertility requirements, they should actively choose appropriate treatments to solve fertility problems along with hormone replacement therapy. Ovulation promotion therapy For patients with premature ovarian failure with fertility requirements, ovulation promotion therapy is usually performed by suppressing endogenous gonadotropins (mainly FSH) to low levels (<20IU/L) with HRT or GnRHa, and then giving sufficient HMG/HCG to promote ovulation, along with ultrasound follicle monitoring. Successful pregnancies after ovulation-promoting treatment in patients with premature ovarian failure have indeed been reported, but these methods were later confirmed to be ineffective in the literature, such as the belief that a slight increase in pregnancy is associated with close monitoring and guided intercourse, which can also be explained by a natural intermittent recovery of ovarian function. Therefore, it is not medically advisable to blindly recommend patients to use gonadotropins to promote ovulation. More correctly, patients should be advised to go to the hospital for follicle monitoring when they feel symptoms of increased estrogen (e.g. increased vaginal discharge, breast swelling and pain, etc.). When a dominant follicle is found, depending on the patient's condition, technical measures such as coitus, IUI, in vitro fertilization with natural cycle/modified natural cycle, etc. should be taken to try to conceive. 2.Egg donation and embryo transfer The current method to solve the fertility problem of patients with premature ovarian failure is still egg donation and embryo transfer in hormone replacement cycle. First, before embryo transfer, patients with premature ovarian failure should be given 5-6 cycles of estrogen and progesterone replacement therapy to induce cyclic changes in the hypothalamic-pituitary-ovarian axis, to promote endometrial proliferation, maturation and shedding, to prepare for embryo transfer, and to induce endogenous LH peak and endometrial estrogen and progesterone receptor production. Hormone replacement can be performed in two regimens: gradual increments and constant doses. The former hormone fluctuation is similar to the physiological condition, the dose varies with the time of administration, the drug compliance is poor, the time available for embryo transfer is about 3-5 days per cycle, and it is difficult to achieve the synchronization between egg donor and egg recipient; the latter uses a single dose of estrogen and progestin, the compliance is good, and it is widely used at present. Secondly, the donor's menstrual cycle is understood, the day of menstruation is estimated, and the recipient starts taking 1-4 mg of estradiol valerate (E2V) orally daily 3-5 days before the estimated day of ovulation in the donor, and the dose is adjusted according to the thickness and morphology of the endometrium monitored by vaginal ultrasound. Again, 100mg daily starting on the day of transplantation (third day of transplantation after egg retrieval) to simulate a natural cycle and early pregnancy, with E2V and P maintained until about 90 days of gestation. Pregnancy rates of up to 50% in fresh embryo transfer cycles have been reported in the literature for embryo transfer with egg donation in patients with premature ovarian failure. However, there are controversies regarding ethical and legal aspects of egg donation, and the source of eggs is a treatment bottleneck.